PHIO PHARMACEUTICALS CORP. Contractual Obligation
PHIO PHARMACEUTICALS CORP. (PHIO) had Contractual Obligation of $400.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity
us-gaap:ContractualObligation · last filed 2026-03-05
- 2025-12-31: Contractual Obligation $400.00K.
- 2024-12-31: Contractual Obligation $500.00K.
- 2023-12-31: Contractual Obligation $600.00K.
- 2022-12-31: Contractual Obligation $700.00K.
| Period end | Contractual Obligation |
|---|---|
| 2025-12-31 | $400.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $500.00K 10-K · filed 2025-03-31 |
| 2023-12-31 | $600.00K 10-K · filed 2024-04-01 |
| 2022-12-31 | $700.00K 10-K · filed 2023-03-22 |
| 2022-06-30 | $4.00M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $4.00M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $800.00K 10-K · filed 2022-03-22 |
| 2020-12-31 | $965.00K 10-K · filed 2021-03-25 |
| 2019-12-31 | $1.13M 10-K · filed 2020-03-26 |
| 2018-12-31 | $1.29M 10-K · filed 2019-03-27 |
| 2017-12-31 | $1.50M 10-K · filed 2018-03-26 |
| 2016-12-31 | $1.70M 10-K · filed 2017-03-30 |
| 2015-12-31 | $1.90M 10-K · filed 2016-03-30 |
| 2014-12-31 | $1.61M 10-K · filed 2015-03-30 |
| 2013-12-31 | $1.69M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |